183
Participants
Start Date
June 30, 2007
Primary Completion Date
July 31, 2010
Study Completion Date
September 30, 2010
MEDI 545
"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
Placebo
"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
Research Site, New York
Research Site, New York
Research Site, Manhasset
Research Site, Bethesda
Research Site, Baltimore
Research Site, Greenville
Research Site, Fort Lauderdale
Research Site, Tampa
Research Site, Ocala
Research Site, Anniston
Research Site, Clearwater
Research Site, Shreveport
Research Site, Dallas
Research Site, Los Angeles
Research Site, Portland
Research Site, La Jolla
Research Site, Oklahoma City
Research Site, Buenos Aires
Research Site, São Paulo
Research Site, Santiago
Research Site, Dallas
Research Site, San Miguel de Tucumán
Research Site, Curitiba
Lead Sponsor
MedImmune LLC
INDUSTRY